CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

08.05.2017

## ONLINE INTIMATION/SUBMISSION

BSE Limited
Department of Corporate Relationship
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd., Department of Corporate Services Exchange Plaza, 5<sup>th</sup> Floor, C-1, Block G,Bandra Kurla Complex, Bandra (E),Mumbai – 400 051 Scrip Code: CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: PRESS RELEASE - DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed copy of press release being issued today.

Thanking you,

Yours Faithfully,

For Caplin Point Laboratories Limited

Company Secretary Enclosure : As Above



CIN: L24231TN1990PLC019053

Regd. Off.: "NARBAVI", No.3, Lakshmanan Street, T. Nagar, Chennai - 600 017. Tamil Nadu, India. Phone: +91 44 28156653, 28156905 Fax: +91 44 28154952 E-mail: info@caplinpoint.net Website: www.caplinpoint.net

## CAPLIN POINT GETS EIR FOR USFDA FOR STERILE INJECTABLE SITE

**CHENNAI, MAY 8, 2017: CAPLIN POINT LABORATORIES LIMITED** (BSE: CAPLL (524742), NSE: CAPLIPOINT) Caplin Point has received the Establishment Inspection Report (EIR) from USFDA for the inspection carried out during Oct 21<sup>st</sup> – 27<sup>th</sup>, 2016 at its sterile injectable plant at Gummidipoondi, Tamil Nadu.

"We're pleased with this nod from the USFDA for our injectable site. It's a major milestone in our journey into the Regulated Markets. This will pave the way for our entry into the largest Pharma market in the world" said C.C.Paarthipan, Chairman of Caplin Point Laboratories Ltd.

The facility, capable of manufacturing Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages, is also approved by EU-GMP and ANVISA-Brazil.

## **ABOUT CAPLIN POINT LABORATORIES LIMITED:**

Caplin Point Laboratories Limited is a niche pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.

Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company currently holds over 2200 product licenses across Latin America and Africa with another 350 in the pipeline.

Caplin Point has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), one of the very few companies to appear on the list for three successive years.

## **CAUTIONARY STATEMENT:**

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or amission here from which may become apparent.